Higher-Dose ANGPTL3 Inhibitor Cuts Lipids but With Questionable Safety Significant safety signals in dose-ranging trial may end drug's future in CV prevention Apr 03, 2022
Tranexamic Acid Cuts Surgical Bleeding in Yet Another Setting But POISE-3 trial leaves open the question of cardiovascular safety Apr 02, 2022
From 'Pre-HF' to 'HFimpEF': Guidelines Redefine Heart Failure Stages, Classes Update also adds SGLT2 inhibitor as a pillar of therapy Apr 01, 2022
Cardiomyopathy: Epidemiology, Etiology, and Pathophysiology A brief guide through the wide range of cardiomyopathies Apr 01, 2022
For Your Patients: How to Prepare for Your Cardiomyopathy Appointment Questions to ask your cardiologist, and answers you might need Apr 01, 2022
Antiplatelets Don't Get Critically Ill COVID Patients Off Ventilation Sooner REMAP-CAP trial weighs in on addition of aspirin, P2Y12 inhibitors Mar 22, 2022
In HFpEF, Do MRA Users Get as Much Benefit From an SGLT2 Inhibitor? EMPEROR-Preserved trial weighs in Mar 21, 2022
More Clues Emerge for Brain Bleed Prognosis Large study identifies some novel risk factors for mortality, disability Mar 15, 2022
'Exceptional' ECMO Outcomes in COVID-19 Reflect Early Choices When not used for last-ditch salvage, high proportion survive and recover lung function Mar 10, 2022
Ross Procedure Best for Fixing Aortic Valve in Younger Patients? Propensity-matched analysis may suggest it's time for "Ross Centers of Excellence" Mar 07, 2022